Skip to main content
Erschienen in: AIDS and Behavior 8/2021

17.03.2021 | Original Paper

The Hepatitis C Continuum of Care Among HIV-Positive Persons with Heavy Alcohol Use in St. Petersburg, Russia

verfasst von: Maria A. Corcorran, Natasha Ludwig-Baron, Debbie M. Cheng, Dmitry Lioznov, Natalia Gnatienko, Gregory Patts, Kaku So-Armah, Elena Blokhina, Sally Bendiks, Evgeny Krupitsky, Jeffrey H. Samet, Judith I. Tsui

Erschienen in: AIDS and Behavior | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

This study describes the self-reported prevalence of hepatitis C virus (HCV) coinfection and the HCV care continuum among persons enrolled in the St PETER HIV Study, a randomized controlled trial of medications for smoking and alcohol cessation in HIV-positive heavy drinkers and smokers in St. Petersburg, Russia. Baseline health questionnaire data were used to calculate proportions and 95% confidence intervals for self-reported steps along the HCV continuum of care. The cohort included 399 HIV-positive persons, of whom 387 [97.0% (95% CI 95.3–98.7%)] reported a prior HCV test and 315 [78.9% (95% CI 74.9–82.9%)] reported a prior diagnosis of HCV. Among those reporting a diagnosis of HCV, 43 [13.7% (95% CI 9.9–17.4%)] had received treatment for HCV, and 31 [9.8% (95% CI 6.6–13.1%)] had been cured. Despite frequent HCV testing in this HIV-positive Russian cohort, the proportion reporting prior effective HCV treatment was strikingly low. Increased efforts are needed to scale-up HCV treatment among HIV-positive Russians in St. Petersburg.
Literatur
3.
Zurück zum Zitat Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010;12(5):448–53.PubMedPubMedCentral Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010;12(5):448–53.PubMedPubMedCentral
4.
Zurück zum Zitat Larney S, Leung J, Grebely J, et al. Global systematic review and ecological analysis of HIV in people who inject drugs: national population sizes and factors associated with HIV prevalence. Int J Drug Policy. 2020;77:102656.PubMed Larney S, Leung J, Grebely J, et al. Global systematic review and ecological analysis of HIV in people who inject drugs: national population sizes and factors associated with HIV prevalence. Int J Drug Policy. 2020;77:102656.PubMed
5.
Zurück zum Zitat Niccolai LM, Toussova OV, Verevochkin SV, Barbour R, Heimer R, Kozlov AP. High HIV prevalence, suboptimal HIV testing, and low knowledge of HIV-positive serostatus among injection drug users in St. Petersburg Russia. AIDS Behav. 2010;14(4):932–41.PubMedPubMedCentral Niccolai LM, Toussova OV, Verevochkin SV, Barbour R, Heimer R, Kozlov AP. High HIV prevalence, suboptimal HIV testing, and low knowledge of HIV-positive serostatus among injection drug users in St. Petersburg Russia. AIDS Behav. 2010;14(4):932–41.PubMedPubMedCentral
6.
Zurück zum Zitat Eritsyan K, Heimer R, Barbour R, et al. Individual-level, network-level and city-level factors associated with HIV prevalence among people who inject drugs in eight Russian cities: a cross-sectional study. BMJ Open. 2013;3(6):e002645.PubMedPubMedCentral Eritsyan K, Heimer R, Barbour R, et al. Individual-level, network-level and city-level factors associated with HIV prevalence among people who inject drugs in eight Russian cities: a cross-sectional study. BMJ Open. 2013;3(6):e002645.PubMedPubMedCentral
7.
Zurück zum Zitat Heimer R, Usacheva N, Barbour R, Niccolai LM, Uusküla A, Levina OS. Engagement in HIV care and its correlates among people who inject drugs in St Petersburg, Russian Federation and Kohtla-Järve Estonia. Addiction. 2017;112(8):1421–31.PubMedPubMedCentral Heimer R, Usacheva N, Barbour R, Niccolai LM, Uusküla A, Levina OS. Engagement in HIV care and its correlates among people who inject drugs in St Petersburg, Russian Federation and Kohtla-Järve Estonia. Addiction. 2017;112(8):1421–31.PubMedPubMedCentral
8.
Zurück zum Zitat Rhodes T, Platt L, Maximova S, et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction. 2006;101(2):252–66.PubMed Rhodes T, Platt L, Maximova S, et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction. 2006;101(2):252–66.PubMed
9.
Zurück zum Zitat Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83.PubMedPubMedCentral Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83.PubMedPubMedCentral
10.
Zurück zum Zitat Heimer R, Eritsyan K, Barbour R, Levina OS. Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities. BMC Infect Dis. 2014;14(Suppl 6):S12.PubMedPubMedCentral Heimer R, Eritsyan K, Barbour R, Levina OS. Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities. BMC Infect Dis. 2014;14(Suppl 6):S12.PubMedPubMedCentral
11.
Zurück zum Zitat Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625–34.PubMed Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625–34.PubMed
12.
Zurück zum Zitat Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet GastroenterolHepatol. 2018;3(11):754–67. Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet GastroenterolHepatol. 2018;3(11):754–67.
13.
Zurück zum Zitat Morris L, Smirnov A, Kvassay A, et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland injectors’ health network. Int J Drug Policy. 2017;47:216–20.PubMed Morris L, Smirnov A, Kvassay A, et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland injectors’ health network. Int J Drug Policy. 2017;47:216–20.PubMed
14.
Zurück zum Zitat Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norris S. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS ONE. 2017;12(6):e0178398.PubMedPubMedCentral Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norris S. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS ONE. 2017;12(6):e0178398.PubMedPubMedCentral
15.
Zurück zum Zitat American Association for the Study of Liver Disease (AASLD) and Infectious Diseases Society of America (IDSA). Recommendations for testing, managing, and treating hepatitis C. 2019. https://www.hcvguidelines.org/. Accessed 13 Feb 2020. American Association for the Study of Liver Disease (AASLD) and Infectious Diseases Society of America (IDSA). Recommendations for testing, managing, and treating hepatitis C. 2019. https://​www.​hcvguidelines.​org/​. Accessed 13 Feb 2020.
20.
Zurück zum Zitat McLellan AT, Luborsky L, Cacciola J, et al. New data from the addiction severity index. Reliability and validity in three centers. J NervMent Dis. 1985;173(7):412–23. McLellan AT, Luborsky L, Cacciola J, et al. New data from the addiction severity index. Reliability and validity in three centers. J NervMent Dis. 1985;173(7):412–23.
21.
Zurück zum Zitat National Health Interview Survey (ICPSR 2954). United States department of health and human services, National center for health statistics; 1997. National Health Interview Survey (ICPSR 2954). United States department of health and human services, National center for health statistics; 1997.
22.
Zurück zum Zitat Sobell L, Sobell M. Alcohol timeline followback (TLFB) users’ manual. Toronto: Alcohol Research Foundation; 1995. Sobell L, Sobell M. Alcohol timeline followback (TLFB) users’ manual. Toronto: Alcohol Research Foundation; 1995.
23.
Zurück zum Zitat Babor T, Higgins-Biddle J, Saunders J, Monteiro M. Audit The Alcohol Use Disorders Identification Test (AUDIT): Guidelines for use in primary care; 2001. Babor T, Higgins-Biddle J, Saunders J, Monteiro M. Audit The Alcohol Use Disorders Identification Test (AUDIT): Guidelines for use in primary care; 2001.
24.
Zurück zum Zitat Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28(1):154–62.PubMed Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28(1):154–62.PubMed
25.
Zurück zum Zitat Sobell L, Sobell M, Buchan G, et al. Timeline Followback Method (Drugs, Cigarettes, and Marijuana); 1996. Sobell L, Sobell M, Buchan G, et al. Timeline Followback Method (Drugs, Cigarettes, and Marijuana); 1996.
26.
Zurück zum Zitat Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient care committee & adherence working group of the outcomes committee of the adult AIDS clinical trials group (AACTG). AIDS Care. 2000;12(3):255–66.PubMed Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient care committee & adherence working group of the outcomes committee of the adult AIDS clinical trials group (AACTG). AIDS Care. 2000;12(3):255–66.PubMed
27.
Zurück zum Zitat Weatherby N, Needle R, Cesari H, et al. Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Program Plann. 1994;17(4):347–55. Weatherby N, Needle R, Cesari H, et al. Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Program Plann. 1994;17(4):347–55.
28.
Zurück zum Zitat Needle R, Fisher D, Weatherby N, et al. Reliability of self-reported hiv risk behaviors of drug users. Psychol Addict Behav. 1995;9(4):242–50. Needle R, Fisher D, Weatherby N, et al. Reliability of self-reported hiv risk behaviors of drug users. Psychol Addict Behav. 1995;9(4):242–50.
29.
Zurück zum Zitat Britton PC, Bohnert AS, Wines JD, Conner KR. A procedure that differentiates unintentional from intentional overdose in opioid abusers. Addict Behav. 2012;37(1):127–30.PubMed Britton PC, Bohnert AS, Wines JD, Conner KR. A procedure that differentiates unintentional from intentional overdose in opioid abusers. Addict Behav. 2012;37(1):127–30.PubMed
30.
Zurück zum Zitat Kazis LE, Miller DR, Clark J, et al. Health-related quality of life in patients served by the Department of veterans affairs: results from the veterans health study. Arch Intern Med. 1998;158(6):626–32.PubMed Kazis LE, Miller DR, Clark J, et al. Health-related quality of life in patients served by the Department of veterans affairs: results from the veterans health study. Arch Intern Med. 1998;158(6):626–32.PubMed
31.
Zurück zum Zitat Miller W. Form 90: A structured assessment interview for drinking and related behaviors: Test manual US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism; 1996. Miller W. Form 90: A structured assessment interview for drinking and related behaviors: Test manual US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism; 1996.
32.
Zurück zum Zitat Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808.PubMed Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808.PubMed
33.
Zurück zum Zitat Rhodes T, Platt L, Judd A, et al. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Int J STD AIDS. 2005;16(11):749–54.PubMed Rhodes T, Platt L, Judd A, et al. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Int J STD AIDS. 2005;16(11):749–54.PubMed
34.
Zurück zum Zitat Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? Ecol Anal Addict. 2010;105(2):311–8. Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? Ecol Anal Addict. 2010;105(2):311–8.
35.
Zurück zum Zitat Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.PubMedPubMedCentral Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.PubMedPubMedCentral
36.
Zurück zum Zitat Perlman DC, Jordan AE, Uuskula A, et al. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: structural barriers and public health potential. Int J Drug Policy. 2015;26(11):1056–63.PubMedPubMedCentral Perlman DC, Jordan AE, Uuskula A, et al. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: structural barriers and public health potential. Int J Drug Policy. 2015;26(11):1056–63.PubMedPubMedCentral
37.
Zurück zum Zitat Luhmann N, Champagnat J, Golovin S, et al. Access to hepatitis C treatment for people who inject drugs in low and middle income settings: evidence from 5 countries in Eastern Europe and Asia. Int J Drug Policy. 2015;26(11):1081–7.PubMed Luhmann N, Champagnat J, Golovin S, et al. Access to hepatitis C treatment for people who inject drugs in low and middle income settings: evidence from 5 countries in Eastern Europe and Asia. Int J Drug Policy. 2015;26(11):1081–7.PubMed
38.
Zurück zum Zitat Chikovani I, Ompad DC, Uchaneishvili M, et al. On the way to hepatitis C elimination in the Republic of Georgia-barriers and facilitators for people who inject drugs for engaging in the treatment program: a formative qualitative study. PLoS ONE. 2019;14(4):e0216123.PubMedPubMedCentral Chikovani I, Ompad DC, Uchaneishvili M, et al. On the way to hepatitis C elimination in the Republic of Georgia-barriers and facilitators for people who inject drugs for engaging in the treatment program: a formative qualitative study. PLoS ONE. 2019;14(4):e0216123.PubMedPubMedCentral
39.
Zurück zum Zitat Amele S, Peters L, Sluzhynska M, et al. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. HIV Med. 2019;20(4):264–73.PubMed Amele S, Peters L, Sluzhynska M, et al. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. HIV Med. 2019;20(4):264–73.PubMed
40.
Zurück zum Zitat Peters L, Laut K, Resnati C, et al. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. AIDS. 2018;32(14):1995–2004.PubMed Peters L, Laut K, Resnati C, et al. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. AIDS. 2018;32(14):1995–2004.PubMed
41.
Zurück zum Zitat Dara M, Ehsani S, Mozalevskis A, et al. Tuberculosis, HIV, and viral hepatitis diagnostics in Eastern Europe and central Asia: high time for integrated and people-centred services. Lancet Infect Dis. 2020;20(2):e47–53.PubMed Dara M, Ehsani S, Mozalevskis A, et al. Tuberculosis, HIV, and viral hepatitis diagnostics in Eastern Europe and central Asia: high time for integrated and people-centred services. Lancet Infect Dis. 2020;20(2):e47–53.PubMed
42.
Zurück zum Zitat Lions C, Laroche H, Zaegel-Faucher O, et al. Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit. Eur J GastroenterolHepatol. 2019;32(9):1212–21. Lions C, Laroche H, Zaegel-Faucher O, et al. Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit. Eur J GastroenterolHepatol. 2019;32(9):1212–21.
43.
Zurück zum Zitat Boerekamps A, van den Berk GE, Lauw FN, et al. Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis. 2018;66(9):1360–5.PubMed Boerekamps A, van den Berk GE, Lauw FN, et al. Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis. 2018;66(9):1360–5.PubMed
44.
Zurück zum Zitat Boerekamps A, Newsum AM, Smit C, et al. High treatment uptake in human immunodeficiency virus/hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands. Clin Infect Dis. 2018;66(9):1352–9.PubMed Boerekamps A, Newsum AM, Smit C, et al. High treatment uptake in human immunodeficiency virus/hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands. Clin Infect Dis. 2018;66(9):1352–9.PubMed
45.
Zurück zum Zitat Kracht PAM, Arends JE, van Erpecum KJ, et al. Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. Hepatol Med Policy. 2018;3:12.PubMedPubMedCentral Kracht PAM, Arends JE, van Erpecum KJ, et al. Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. Hepatol Med Policy. 2018;3:12.PubMedPubMedCentral
46.
Zurück zum Zitat Overton K, Clegg J, Pekin F, et al. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting. Int J Drug Policy. 2019;72:123–8.PubMed Overton K, Clegg J, Pekin F, et al. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting. Int J Drug Policy. 2019;72:123–8.PubMed
47.
Zurück zum Zitat Papaluca T, McDonald L, Craigie A, et al. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care. J Hepatol. 2019;7(5):839–46. Papaluca T, McDonald L, Craigie A, et al. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care. J Hepatol. 2019;7(5):839–46.
48.
Zurück zum Zitat Morey S, Hamoodi A, Jones D, et al. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. J Viral Hepat. 2019;26(1):101–8.PubMed Morey S, Hamoodi A, Jones D, et al. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. J Viral Hepat. 2019;26(1):101–8.PubMed
49.
Zurück zum Zitat Bielen R, Stumo SR, Halford R, et al. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduct J. 2018;15(1):25.PubMedPubMedCentral Bielen R, Stumo SR, Halford R, et al. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduct J. 2018;15(1):25.PubMedPubMedCentral
50.
Zurück zum Zitat Bhandari R, Morey S, Hamoodi A, et al. High rate of hepatitis C reinfection following antiviral treatment in the North East England prisons. J Viral Hepat. 2019;27(4):449–52.PubMed Bhandari R, Morey S, Hamoodi A, et al. High rate of hepatitis C reinfection following antiviral treatment in the North East England prisons. J Viral Hepat. 2019;27(4):449–52.PubMed
51.
Zurück zum Zitat Stöver H, Meroueh F, Marco A, et al. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe. BMC Public Health. 2019;19(1):30.PubMedPubMedCentral Stöver H, Meroueh F, Marco A, et al. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe. BMC Public Health. 2019;19(1):30.PubMedPubMedCentral
52.
Zurück zum Zitat Marco A, Roget M, Cervantes M, et al. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates. J Viral Hepat. 2018;25(11):1280–6.PubMed Marco A, Roget M, Cervantes M, et al. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates. J Viral Hepat. 2018;25(11):1280–6.PubMed
53.
Zurück zum Zitat Jülicher P, Chulanov VP, Pimenov NN, Chirkova E, Yankina A, Galli C. Streamlining the screening cascade for active Hepatitis C in Russia: a cost-effectiveness analysis. PLoS ONE. 2019;14(7):e0219687.PubMedPubMedCentral Jülicher P, Chulanov VP, Pimenov NN, Chirkova E, Yankina A, Galli C. Streamlining the screening cascade for active Hepatitis C in Russia: a cost-effectiveness analysis. PLoS ONE. 2019;14(7):e0219687.PubMedPubMedCentral
54.
Zurück zum Zitat Barber MJ, Gotham D, Khwairakpam G, Hill A. Price of a hepatitis C cure: cost of production and current prices for direct-acting antivirals in 50 countries. J Virus Erad. 2020;6(3):100001.PubMedPubMedCentral Barber MJ, Gotham D, Khwairakpam G, Hill A. Price of a hepatitis C cure: cost of production and current prices for direct-acting antivirals in 50 countries. J Virus Erad. 2020;6(3):100001.PubMedPubMedCentral
55.
Zurück zum Zitat Jo Y, Bartholomew TS, Doblecki-Lewis S, et al. Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida. PLoS ONE. 2020;15(4):e0231424.PubMedPubMedCentral Jo Y, Bartholomew TS, Doblecki-Lewis S, et al. Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida. PLoS ONE. 2020;15(4):e0231424.PubMedPubMedCentral
56.
Zurück zum Zitat Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut. 2001;49(3):423–30.PubMedPubMedCentral Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut. 2001;49(3):423–30.PubMedPubMedCentral
57.
Zurück zum Zitat Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-68.PubMed Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-68.PubMed
58.
Zurück zum Zitat Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 2016;169:101–9.PubMedPubMedCentral Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 2016;169:101–9.PubMedPubMedCentral
59.
Zurück zum Zitat So-Armah K, Freiberg M, Cheng D, et al. Liver fibrosis and accelerated immune dysfunction (immunosenescence) among HIV-infected Russians with heavy alcohol consumption—An observational cross-sectional study. BMC Gastroenterol. 2019;20(1):1.PubMedPubMedCentral So-Armah K, Freiberg M, Cheng D, et al. Liver fibrosis and accelerated immune dysfunction (immunosenescence) among HIV-infected Russians with heavy alcohol consumption—An observational cross-sectional study. BMC Gastroenterol. 2019;20(1):1.PubMedPubMedCentral
Metadaten
Titel
The Hepatitis C Continuum of Care Among HIV-Positive Persons with Heavy Alcohol Use in St. Petersburg, Russia
verfasst von
Maria A. Corcorran
Natasha Ludwig-Baron
Debbie M. Cheng
Dmitry Lioznov
Natalia Gnatienko
Gregory Patts
Kaku So-Armah
Elena Blokhina
Sally Bendiks
Evgeny Krupitsky
Jeffrey H. Samet
Judith I. Tsui
Publikationsdatum
17.03.2021
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 8/2021
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03214-y

Weitere Artikel der Ausgabe 8/2021

AIDS and Behavior 8/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.